Cancer diagnosis & prognosis最新文献

{"title":"Pleomorphic Rhabdomyosarcoma of the Uterine Corpus in an Adult Who Underwent Multi-gene Panel Testing.","authors":"Tamami Odai, Noriko Oshima, Yusuke Kori, Maki Takao, Kimio Wakana, Naoyuki Miyasaka","doi":"10.21873/cdp.10333","DOIUrl":"https://doi.org/10.21873/cdp.10333","url":null,"abstract":"<p><strong>Background/aim: </strong>Rhabdomyosarcoma (RMS) is the most common malignant soft tissue tumor in children. Adult primary RMS of gynecological origin is a rare condition and uterine RMS is an aggressive malignancy with a poor prognosis. The genetic variants associated with uterine RMS in adults have yet to be fully elucidated, and there is no established therapeutic strategy for rare tumors.</p><p><strong>Case report: </strong>A 69-year-old Japanese woman was referred to our hospital with abdominal bloating. Imaging examination revealed a tumor with diameter of 85 mm located in the uterus and multiple regional lymph node metastases. Biopsy of the uterine corpus indicated possible uterine carcinosarcoma or RMS. Following debulking surgery, the patient was diagnosed with stage IVB pleomorphic RMS. The patient was treated with two courses of doxorubicin every three weeks and one course of combination chemotherapy with vincristine, actinomycin, and cyclophosphamide. Because of rapid progression of the disease, we decided to perform multi-gene panel testing to determine the most effective therapeutic strategy. However, no therapeutic plan based on genetic information was identified. The patient with chemotherapy-refractory RMS died 11 weeks after surgery.</p><p><strong>Conclusion: </strong>Our patient had advanced uterine RMS with an unresectable tumor that was resistant to chemotherapy, resulting in poor outcomes. Despite conducting multi-gene panel testing, no tailored therapeutic approach based on genetic information was found. This case highlights the challenges in managing uterine RMS in adults and underscores the urgent need for further research to identify effective treatment modalities.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140873663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the Difference in Quality of Life Between Immediate and Delayed Breast Cancer Reconstruction: A Systematic Review.","authors":"Vlasios Tsantakis, Dimitrios A Dimitroulis, Konstantinos C Kontzoglou, Nikolaos I Nikiteas","doi":"10.21873/cdp.10312","DOIUrl":"https://doi.org/10.21873/cdp.10312","url":null,"abstract":"<p><strong>Background/aim: </strong>Immediate and delayed breast reconstruction remains a controversial topic. Apart from the clinical outcomes that have to be considered, there is a discrepancy of opinions regarding the potential differences in quality of life. It is essential to clarify this issue, in order to contribute to the reconstruction of the decision-making process. The aim of the study was to investigate potential differences in quality of life between immediate and delayed breast reconstruction patients.</p><p><strong>Materials and methods: </strong>A systematic review of the literature was carried out, searching for case-control studies that have comparatively examined the effects of delayed and immediate reconstruction on quality of life. A literature search was carried out using the Medline, Scopus and Web of Science databases. The quality of the studies was evaluated using the STROBE checklist for case-control studies.</p><p><strong>Results: </strong>Three studies were found showing that immediate reconstruction led to benefits for the quality of life of patients, while one study showed the opposite. A relevant study revealed no statistically significant differences between the two groups, while another study, showed that immediate reconstruction entailed short-term benefits to quality of life. Four of the studies had debatable methodological approaches.</p><p><strong>Conclusion: </strong>The inconsistent study findings cannot lead to any reliable conclusions regarding differences between immediate and delayed reconstruction in quality of life. It is possible that the results vary due to the time point that the comparisons made. Future research to this direction is warranted.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140859195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Speedy/RINGO Protein in Breast Cancer as a Future Biomarker.","authors":"Ozgur Tanriverdi, Aysegul Yildiz","doi":"10.21873/cdp.10310","DOIUrl":"https://doi.org/10.21873/cdp.10310","url":null,"abstract":"<p><strong>Background/aim: </strong>Cyclin-dependent kinases (CDKs) are proteins that require the binding of regulatory subunits called cyclins and play a key role in cell cycle progression and activation. CDKs play a key role in carcinogenesis of many solid malignancies, and inhibition of these proteins has produced anti-cancer effects demonstrated in preclinical studies. This narrative review was conducted to develop a hypothetical approach to determine whether Speedy/RINGO, a protein associated with CDK2, could be a possible predictive factor in breast cancer patients treated with a CDK4/6 inhibitor.</p><p><strong>Materials and methods: </strong>A literature search was conducted in PubMed, Web of Science, Medline, and Google Scholars search engines to match the following words: \"Speedy/RINGO\" or \"Spy1\" and \"CDKs\" or \"Cyclin-dependent kinases (CDKs)\" and \"CDK4/6 inhibitors\" and \"Regulation\" and \"Molecular\" and \"Breast cancer\" and \"Carcinogenesis\". Only articles investigating the relationship between the Speedy/RINGO protein and CDKs at the molecular level were included. Literature information was compiled by trying to establish a relationship with our hypothesis question.</p><p><strong>Results: </strong>Speedy/RINGO is a tightly regulated proto-oncogenic mammalian protein playing important roles in the somatic cell cycle. Studies have emphasized that although it does not have amino acid sequence homology with cyclins, it can activate CDK2. In addition, results showing molecular compensation of CDK4/6 inhibition through CDK2 activation, also showed that CDK2 can predict drug resistance. Another important finding was that overexpressed Speedy/RINGO, during CDK4/6 inhibitor treatment, could strongly activate CDK2, resulting in a negative response to treatment.</p><p><strong>Conclusion: </strong>Although many predictive factors have been investigated to indicate response to CDK4/6 inhibitors or determine drug resistance, a consensus biomarker has yet to be established. In light of the information obtained from our review, it can be concluded that the Speedy/RINGO protein may have an important role as a predictive biomarker in terms of response to treatment, continuity of treatment and drug resistance in patients treated with CDK4/6 inhibitors.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062167/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal Failure Without Hemodialysis Is a Risk Factor for Postoperative Complications in Colorectal Cancer Surgery.","authors":"Takaaki Fujimoto, Shigetaka Inoue, Taketo Matsunaga, Toru Shimizu, Haruka Mitsubuchi, Takahito Matsuyoshi, Kaou Matsuda, Soshi Terasaka, Takaharu Yasui, Chizu Kameda, Yasuhiro Ogura, Junji Ueda, Kentaro Nakai, Masanori Tokumoto, Kenichi Nishiyama, Kentaro Motoyama, Eishi Nagai, Yuji Nakafusa","doi":"10.21873/cdp.10323","DOIUrl":"https://doi.org/10.21873/cdp.10323","url":null,"abstract":"<p><strong>Background/aim: </strong>Surgical outcomes of colorectal cancer (CRC) in patients with renal failure (RF) remain to be clarified. The objective of this research was to investigate how RF impacts the surgical outcomes in patients with CRC.</p><p><strong>Patients and methods: </strong>A retrospective analysis was performed on clinical data from 633 patients who underwent colorectal resection for CRC between January 2017 and December 2021. Outcomes of the patients with and without RF were compared. RF was defined as estimated Glomerular Filtration Rate less than 30.</p><p><strong>Results: </strong>Forty-five (7%) patients with RF were identified. RF was a significant risk factor for postoperative complications after colorectal cancer surgery (odds ratio=2.19, 95% confidence interval=1.08-4.42, p=0.0284). The patients with RF had significantly more comorbidity (p=0.016), and higher American Society of Anesthesiologists physical status (p<0.01). Hemoglobin level (p<0.01) and PNI (p<0.01) were significantly lower in those with RF. Postoperative complications were significantly higher (p=0.016), and the postoperative hospital stay was significantly longer (p<0.01) among patients with RF compared to those without RF. Patients with RF, excluding those undergoing hemodialysis, had significantly more complications compared to those without RF (p=0.004).</p><p><strong>Conclusion: </strong>Careful attention should be paid to perioperative management in RF colorectal cancer patients.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140863854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative Lymph Node Recurrence in Esophageal Cancer After Surgery and Prognosis of Chemoradiotherapy.","authors":"Manabu Emi, Yoichi Hamai, Toru Yoshikawa, Ryosuke Hirohata, Manato Ohsawa, Tomoaki Kurokawa, Yuji Murakami, Ikuno Nishibuchi, Morihito Okada","doi":"10.21873/cdp.10320","DOIUrl":"https://doi.org/10.21873/cdp.10320","url":null,"abstract":"<p><strong>Background/aim: </strong>This study aimed to evaluate the long-term prognosis of definitive chemoradiotherapy and clinical features of postoperative lymph node (LN) recurrence after curative resection of thoracic esophageal squamous cell cancer (ESCC).</p><p><strong>Patients and methods: </strong>A total of 586 patients who underwent radical resection of ESCC at the Hiroshima University Hospital from January 2000 to December 2019 were reviewed retrospectively. This study analyzed the clinical characteristics of 54 patients who developed recurrence in a solitary LN by comparing them to 182 patients who experienced total recurrence. Additionally, we analyzed the prognostic factors of 50 patients who received chemo-radiotherapy (CRT).</p><p><strong>Results: </strong>The results revealed a tendency for a higher incidence of solitary LN recurrence in cases of early esophageal cancer and upper thoracic esophageal cancer among all recurrence cases. The 3-, 5-, and 7-year overall survival (OS) rates were 40.5%, 37.8% and 34.6%, respectively, with a median survival time of 27.9 months. Univariate analysis of OS factors, such as age, depth of the primary tumor at the initial surgery, time to LN recurrence after surgery, site of LN recurrence, and the number of the regional LNs with recurrence showed no significant impact on OS.</p><p><strong>Conclusion: </strong>Approximately 35% of patients with ESCC who experienced LN recurrence after curative resection achieved long-term survival through CRT. Despite the absence of identifiable prognostic factors, CRT proves to be a valuable initial treatment option for LN recurrence.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140868375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose-escalated Salvage Whole-pelvic Radiotherapy for Biochemical Recurrence After Radical Prostatectomy for High-risk Prostate Cancer.","authors":"Shuhei Miyazaki, Yutaro Tasaki, Mika Nakatake, Koichi Honda, Daisuke Nakamura, Akiko Egawa, Nozomi Oki, Kensuke Mitsunari, Yuichiro Nakamura, Ryoichi Imamura, Ryo Toya","doi":"10.21873/cdp.10326","DOIUrl":"https://doi.org/10.21873/cdp.10326","url":null,"abstract":"<p><strong>Background/aim: </strong>To investigate the institutional experience of dose-escalated salvage whole-pelvic radiotherapy (WPRT) with the simultaneous integrated boost (SIB) technique in patients with biochemical recurrence (BCR) after radical prostatectomy for high-risk prostate cancer.</p><p><strong>Patients and methods: </strong>This retrospective study included 21 patients with BCR who received radical prostatectomy for high-risk prostate cancer and underwent salvage RT. Clinical target volume (CTV) of the whole pelvis (CTV56) included the prostate bed, common iliac, external iliac, internal iliac, and obturator lymph node regions. The boost CTV (CTV66) included the prostate bed. Planning target volumes (PTV) were generated by adding a margin of 6-8 mm to CTV (PTV56 and PTV66). Doses of 56.1 and 66 Gy in 33 fractions were delivered to PTV56 and PTV66, respectively.</p><p><strong>Results: </strong>The 5-year biochemical progression-free survival, overall survival, and cause-specific survival rates were 72%, 94%, and 94%, respectively. A grade 3 late genitourinary toxicity event of gross hematuria was observed in one patient (4%). Acute and late toxicities of grade ≥3, other than gross hematuria, were not observed in any patient.</p><p><strong>Conclusion: </strong>Dose-escalated salvage WPRT using the SIB technique provides appropriate tumor control without increasing the incident of significant toxicities.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140872980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maxillary Sinus NUT Carcinoma: A Case Report.","authors":"Sayaka Arai, Ryota Tomioka, Yuri Ueda, Akira Shimizu, Isaku Okamoto, Kiyoaki Tsukahara","doi":"10.21873/cdp.10334","DOIUrl":"https://doi.org/10.21873/cdp.10334","url":null,"abstract":"<p><strong>Background/aim: </strong>Nuclear protein in testis (NUT) carcinoma is extremely rare, occurs in the midline of the body, progresses rapidly and is refractory to treatment; most patients die within a year. Here, we describe a case of maxillary sinus NUT carcinoma presenting with epistaxis and nasal obstruction that was treated as a standard head and neck carcinoma.</p><p><strong>Case report: </strong>The patient was a 41-year-old male with a left buccal swelling; the diagnosis was made of primary NUT carcinoma of the left maxillary sinus and bone metastasis in the cervical spine. After induction chemotherapy with docetaxel plus cisplatin and 5-fluorouracil, the tumor decreased in size, and the patient was further treated with cisplatin and radiation therapy. One month after that, the tumor remained small, however, lung metastasis was observed. Therefore, nivolumab was administered. Cetuximab and paclitaxel were administered after the lung metastasis worsened, but the patient developed progressive disease and died 11 months after diagnosis.</p><p><strong>Conclusion: </strong>Effective treatments for NUT carcinoma have not yet been established. However, early testing to establish the diagnosis may provide useful insights to guide clinical decisions to improve patient outcomes.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062161/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140857217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First Case Report of Bilateral Parotid Lymphoepithelial Carcinoma.","authors":"Willer Everton Feitosa Meneses, Pedro Henrique Cunha Lima DO Rego, Valdenor Neves Feitosa Junior, Herbert Tavares Palmeira, Douglas Henning Pinheiro Aragao, Andre Costa Teixeira, Pedro Lucena DE Aquino, Pedro Miguel Azevedo Pinheiro, Joao Pedro Targino Silva, Francisco Julimar Correia DE Menezes, Matheus Januario DA Silva, Gabriel Gurgel Silva Fernandes","doi":"10.21873/cdp.10336","DOIUrl":"https://doi.org/10.21873/cdp.10336","url":null,"abstract":"<p><strong>Background/aim: </strong>The parotid is the largest salivary gland and is located anteriorly to the sternocleidomastoid muscle and laterally to the ramus of the mandible. Neoplasms in this gland are relatively rare, with 80% being benign and 20% malignant, primarily represented by mucoepidermoid carcinoma. In the head and neck region, lymphoepithelial carcinoma (LEC) accounts for 0.4% of malignant salivary gland tumors.</p><p><strong>Case report: </strong>A 35-year-old man with no previous comorbidities was admitted to a Head and Neck Surgery Specialty Service for a painless right cervical mass of uncertain growth. Extensive diagnostic investigation revealed involvement of the contralateral parotid, associated with systemic lymph node enlargement. Thus, adjuvant radiotherapy was decided by the treating team.</p><p><strong>Conclusion: </strong>This case confirms the heterogeneous features and distinctive behavior that the disease can present, as seen with bilateral parotid LEC.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062164/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140873638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Rare Inflammatory Myofibroblastic Tumor of the Spleen: A Case Report.","authors":"Dimitris Fagkrezos, Marina Kakavelou, Evgenia Charitaki, Spiros Delis, Kleo Papaparaskeva, Charikleia Triantopoulou, Petros Maniatis, Dimosthenis Chrysikos, Theodore Troupis","doi":"10.21873/cdp.10335","DOIUrl":"https://doi.org/10.21873/cdp.10335","url":null,"abstract":"<p><strong>Background/aim: </strong>Inflammatory myofibroblastic tumors (IMTs) are rare, solid, potentially malignant lesions of uncertain etiology. Histologically, IMTs exhibit a combination of lymphocytes and inflammatory cells within a fibroblastic myxoid layer. The diagnosis of IMTs poses a challenge for various medical specialties, including surgeons, pathologists, and oncologists, due to their non-specific clinical presentation. Furthermore, radiologists face difficulties in interpreting computed tomography (CT) or magnetic resonance imaging (MRI) results, which often yield polymorphic and inconclusive findings. Ultimately, histopathologists play a crucial role in reaching a definitive diagnosis based on the tumor's histological characteristics. They are detected in every system of the human body, most commonly in the lungs. Here, we report an uncommon occurrence of IMT in the spleen of a patient with nonspecific abdominal pain.</p><p><strong>Case report: </strong>A 56-year-old Caucasian female presented to Konstantopouleio General Hospital of Nea Ionia, Athens, Greece, with abdominal pain and discomfort. The patient had no significant medical history and normal laboratory tests. An abdominal CT revealed a large mass in the spleen. A splenectomy was performed. Histopathological analysis of the tumor revealed IMTS.</p><p><strong>Conclusion: </strong>Splenic IMT is a rare benign tumor with moderate malignant potential. It lacks a distinct clinical presentation and is typically identified either incidentally or during the examination of abdominal pain.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140873235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-course Radiotherapy for Airway Stenting in Malignant Airway Obstruction: A Case Report and Literature Review.","authors":"Giuseppe Facondo, Chiara Reverberi, Tino Ceschia, Giuseppe Parisi, Gianluca Vullo, Eugenia Moretti, Marco Trovò","doi":"10.21873/cdp.10332","DOIUrl":"https://doi.org/10.21873/cdp.10332","url":null,"abstract":"<p><strong>Background: </strong>Malignant airway obstruction (MAO) secondary to tumor growth occurs in nearly a third of patients with lung cancer and portends a very poor prognosis if untreated. Treatment options include bronchoscopic intervention with tumor debulking, stent placement, endobronchial brachytherapy, or palliative radiotherapy.</p><p><strong>Case report: </strong>This is a report of a 74-year-old woman with a medical history of metastatic lung adenocarcinoma, hospitalized for dyspnea, hemoptysis, and chest pain with a radiographic finding of MAO on chest X-ray and computed tomography. Patient underwent radiation with a total dose of 13 Gy in two once-weekly fractions of 6.5 Gy per fraction. Three days after the end of radiation treatment, chest X-ray showed a completely right lung re-expansion without atelectasis. Two weeks after radiotherapy treatment, the patient was discharged from hospital without pulmonary symptoms.</p><p><strong>Conclusion: </strong>A different fractionation with a lower equivalent dose in 2 Gy fraction compared to literature data showed efficacy in resolving MAO with excellent local control in the first three months of follow-up.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140874034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}